Capstone Therapeutics Enters into a Joint Venture for the Development of Apo E Mimetic Peptide AEM-28 and Analogs and Announces Conference Call
Published: Aug 06, 2012
TEMPE, Ariz. and SUDBURY, Mass., Aug. 3, 2012 (GLOBE NEWSWIRE) -- Capstone Therapeutics Corp. (OTCQB:CAPS) and LipimetiX, LLC, a privately-held biopharmaceutical company, today announced that they have entered into a joint venture to develop a class of drugs targeted for indications related to lowering blood cholesterol levels. The joint venture, LipimetiX Development LLC ("JV"), will develop a family of Apo E mimetic peptides licensed from The UAB Research Foundation ("UABRF"). The University of Alabama at Birmingham ("UAB") is a leading research institution in this field.